External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

External broker reports(aggregated public sources)

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US market</li><li>India formulations mainly comprise oncology products (+33 launches).</li><li>FY21 revenue break-up - Domestic Business: 19%, International Business: 50% (mainly from the US), APIs: 24%</li></ul><div class="content-highlight"><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p></div>

Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US marketIndia formulations mainly comprise oncology products (+33 launches).FY21 revenue break-up - Domestic Business: 19%, International Business: 50% (mainly from the US), APIs: 24%Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Natco Pharma Limited: One-Off Drives Revenues; All Eyes on Future Launches

<p>What should investors do? Natco's share price has grown by ~1.6x over the past five years (from ~Rs 632 in July 2016 to ~Rs 1024 levels in July 2021). We retain our HOLD rating on this stock...</p>
<div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

What should investors do? Natco's share price has grown by ~1.6x over the past five years (from ~Rs 632 in July 2016 to ~Rs 1024 levels in July 2021). We retain our HOLD rating on this stock...
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Natco Pharma Limited: Sequential Domestic Recovery Amid Covid Sales

<p>Natco is a leading player in the domestic oncology segment with a product basket of ~33 products (FY20). Covid related disturbances and pricing pressure notwithstanding, we expect momentum in oncology segment to be decent on the back of incremental launches. New launches in cardio/diabetology segment (CND) is also expected to support overall growth. Going ahead, Natco is looking to launch 10 products a year. We...</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Natco is a leading player in the domestic oncology segment with a product basket of ~33 products (FY20). Covid related disturbances and pricing pressure notwithstanding, we expect momentum in oncology segment to be decent on the back of incremental launches. New launches in cardio/diabetology segment (CND) is also expected to support overall growth. Going ahead, Natco is looking to launch 10 products a year. We...Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Natco Pharma Limited: Covid Drags FY21; New Launches to Drive FY22

India

Natco Pharma Limited manufactures a comprehensive range of branded and generic dosage forms, bulk actives and intermediates for both Indian as well as International markets. The Company's product range is constantly expanded through its own R&D initiative, basic research and also through joint ventures, technology transfers and collaborations.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Natco Pharma (NTCPH IN)

Natco Pharma Limited: One-Off Drives Revenues; All Eyes on Future Launches

Natco has, over the years, developed a knack for manufacturing complex generic products with few competitors, especially for the US market

ICICI Securities Limited

Natco Pharma Limited: Sequential Domestic Recovery Amid Covid Sales

What should investors do? Natco's share price has grown by ~1.6x over the past five years (from ~Rs 632 in July 2016 to ~Rs 1024 levels in July...

ICICI Securities Limited

Natco Pharma Limited: Covid Drags FY21; New Launches to Drive FY22

Natco is a leading player in the domestic oncology segment. Covid related disturbances and pricing pressure notwithstanding, we expect momentum in...

ICICI Securities Limited

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)